NLRP3 and psoriasis: We demonstrate that DMF, an approved clinical treatment for relapsing–remitting multiple sclerosis [49, 59, 60] and psoriasis [61], was an effective NLRP3 inhibitor in both macrophages and microglia, as has been suggested previously [26, 27, 62].